IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares

Stock News

2025/11/07

IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174217431"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174217431\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174217431?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174217431","market":"fut","top_or_hot":-1,"title":"IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares","media":"Stock News","content":"<p>IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMMUNEONCO-B (01541) Executive Director Tian Wenzhi Increases Holdings by 50,000 H Shares\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-11-07 18:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1174217431","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174217431","pubTimestamp":1762512132,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01541":"宜明昂科-B"},"translate_title":"IMMUNEONCO-B(01541)执行董事田文智增持5万股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":1},"content_text":"IMMUNEONCO-B (01541) announced that the board was informed by Dr. Tian Wenzhi, the company's Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company in the open market on November 7, 2025, at an average price of approximately HKD 7.9500 per share. This represents about 0.01% of the company's total issued shares. Following the purchase, Dr. Tian holds an interest in a total of 116 million shares, accounting for 26.90% of the company's total issued share capital as of the announcement date. Dr. Tian expressed confidence in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, he did not rule out further increasing his holdings in the company at an appropriate time.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}